• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Poster: In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

Poster: In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Mar 14, 2023

Poster: Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

Poster: Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

by Elena Iemma | Mar 14, 2023

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides  
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Oct 11, 2022

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final
Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

by Annie De Groot | May 15, 2019

EpiVax_TaspoglutidePoster_14May19
« Older Entries

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline